Vir Biotechnology is a clinical-stage biopharmaceutical company dedicated to enhancing the immune system to improve lives through the discovery and development of innovative medicines targeting serious infectious diseases and cancer. The company boasts a robust clinical-stage portfolio, including programs for chronic hepatitis delta and various dual-masked T-cell engagers aimed at solid tumor indications. Additionally, Vir Biotechnology is engaged in preclinical research across a spectrum of infectious diseases and oncologic malignancies. The company fosters a supportive work environment, emphasizing the importance of its colleagues' success in achieving its mission.